Calidi Biotherapeutics has granted a significant inducement stock option to its newly appointed Chief Executive Officer, Eric Poma, Ph.D. The non-qualified stock option allows Poma to purchase 726,412 shares at an exercise price of $0.469, which corresponds to the company's common stock closing price on April 22, 2025.
The stock option grant is structured with a four-year vesting schedule, designed to incentivize long-term leadership commitment. Initially, 25% of the options will vest on April 22, 2026, with the remaining shares vesting in equal monthly installments through April 22, 2029. This arrangement aligns with Section 711 of the NYSE American LLC Company Guide.
The stock option grant represents a strategic move by Calidi Biotherapeutics, a clinical-stage biotechnology company focused on developing targeted antitumor virotherapies. By offering a substantial equity package, the company signals confidence in Poma's leadership and potential to drive innovation in cancer treatment.
Calidi's proprietary technology centers on utilizing stem cell-based platforms to enhance the immune system's ability to combat cancer. The company's approach involves using allogeneic stem cells to carry oncolytic viruses, potentially improving treatment efficacy and patient safety for conditions like high-grade gliomas and solid tumors.
The stock option grant could be viewed as a key indicator of the company's strategic priorities and commitment to advancing its groundbreaking cancer treatment technologies under new leadership.
